Catalysts
PTGX Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
PTGXProtagonist Therapeutics, Inc.
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum70
- Value72
- Quality81
- Risk resilience70
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 70/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 27.92%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | — | $3.06 | $3.07 | +0.3% | $249.38M | $274.41M |
| Aug 5, 2026 | — | $2.23 | $2.29 | +2.7% | $198.66M | $213.48M |
| May 5, 2026 | — | -$0.65 | $0.05 | +107.7% | $11.7M | $56.37M |
| Feb 25, 2026 | — | -$0.53 | -$0.69 | -30.2% | $8.74M | $7.44M |
| Nov 6, 2025 | — | -$0.59 | -$0.62 | -5.1% | $14.92M | $4.71M |
| Aug 6, 2025 | — | -$0.53 | -$0.55 | -3.8% | $8.43M | $5.55M |
| May 6, 2025 | — | -$0.50 | -$0.19 | +62.0% | $6.56M | $28.32M |
| Feb 21, 2025 | — | $0.06 | $1.98 | +3200.0% | $81.01M | $170.64M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $...
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additional $200 million opt-out fee and a separate $75 million approval milestone. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) chose royalties over the original 50:50 U.S. […]
Related Links
PTGX Catalysts FAQ
What are the next catalysts for PTGX stock?
PTGX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move PTGX stock?
Upcoming events that could move PTGX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could PTGX's next earnings report affect the stock?
PTGX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive PTGX stock higher?
PTGX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt PTGX stock?
PTGX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.